ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE

Ad-RTS-hIL-12 (Ad) is a novel gene therapy, conditionally expressing IL-12 via the RheoSwitch Therapeutic System® (RTS®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported results from 51 subjects (NCT02026271 and NCT03679754) describing biological activity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Lukas, Rimas, Chiocca, Ennio, Kurz, Sylvia, Yu, John, Landolfi, Joseph, Rao, Ganesh, Buck, Jill, Demars, Nathan, Smith, Amy, Miao, John, Zhou, John, Wang, Yunxia, Gelb, Arnold, Cooper, Laurence
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials–Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados